Consensus Prothena Corporation plc

Stocks

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 23/10/2026 +03			5-day change	1st Jan Change
8.200 ^USD	-0.61%		-1.80%	-14.14%

10-15	Prothena Corp Public Ltd Insider Bought Shares Worth $920,049, According to a Recent SEC Filing	MT
10-09	Prothena Corp Public Ltd Insider Bought Shares Worth $1,821,054, According to a Recent SEC Filing	MT

Evolution of the Average Target: Prothena Corporation plc

Evolution of the Target Price: Prothena Corporation plc

Changes in Analyst Recommendations: Prothena Corporation plc

6c16777a3.aCYztMK_ZqjbaDi2HHRbGVRsyMpEI5UWuTuBt150TCc.KkJB25aKUeKBLWrmbR5sbyA9jf0-WqB67m_39i8ABXNRRwv7kcgL94kJXw~7697342fde9c18fbe667393e6fbc7e17

Analysts' recommendations: Prothena Corporation plc

02-20	RBC Raises Price Target on Prothena to $12 From $11, Keeps Sector Perform, Speculative Risk	MT
11-07	RBC Capital Adjusts Prothena Price Target to $11 From $10, Maintains Sector Perform Rating	MT
02/10/25	Prothena's partner Bristol Myers Squibb obtains fast track designation from US FDA for BMS-986446 for treatment of Alzheimer's disease	RE
05/08/25	RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk	MT
28/05/25	BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target	MT
27/05/25	Oppenheimer Downgrades Prothena to Market Perform From Outperform	MT
27/05/25	Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32	MT
27/05/25	Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating	MT
09/05/25	RBC Trims Price Target on Prothena to $18 From $20, Keeps Sector Perform, Speculative Risk	MT
21/02/25	RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk	MT
20/12/24	Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target	MT
14/08/24	Oppenheimer Cuts Prothena Price Target to $62 From $66, Outperform Rating Maintained	MT
09/08/24	RBC Cuts Price Target on Prothena to $24 From $28, Keeps Sector Perform, Speculative Risk	MT
09/05/24	RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk	MT
20/02/24	Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	MT
16/02/24	RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	MT
25/01/24	RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	MT
12/12/23	Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	MT
02/11/23	RBC Cuts Price Target on Prothena to $43 From $60, Keeps Sector Perform, Speculative Risk	MT
04/08/23	JMP Securities Adjusts Prothena's Price Target to $83 From $82, Keeps Market Outperform Rating	MT
08/05/23	Cantor Fitzgerald Adjusts Prothena Price Target to $120 From $98, Maintains Overweight Rating	MT
05/05/23	HC Wainwright Adjusts Price Target on Prothena to $90 From $75, Maintains Buy Rating	MT
05/05/23	RBC Boosts Price Target on Prothena to $60 From $55, Maintains Sector Perform, Speculative Risk	MT
24/04/23	SVB Securities Starts Prothena at Outperform With $80 Price Target	MT
27/02/23	Citigroup Adjusts Price Target on Prothena to $72 From $76, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROTHENA CORPORATION PLC					+160.98%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+36.90%
	Weighted average by Cap.					+23.50%